Post-ERCP Acute Pancreatitis Clinical Trial
— PredERCPOfficial title:
Prediction of Post-Endoscopic Retrograde Cholangio-Pancreatography Pancreatitis Based on the Appearance of the Major Duodenal Papilla: a Prospective, Observational, Cohort Study
NCT number | NCT05800626 |
Other study ID # | 5534 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2023 |
Est. completion date | December 31, 2025 |
This observational, prospective study aims at evaluating how the occurrence of post-Endoscopic Retrograde CholangioPancreatography (ERCP) acute pancreatitis (PEP) could be influenced by difficult biliary cannulation that might be previously assessed by the morphological appearance of native major papilla in all the patients undergoing ERCP. The rate of successful biliary cannulation across papilla types could be used as intraprocedural quality and competence metrics during training. Moreover, recognizing difficult papillae could allow reserving those to experts to decrease the odds of failed cannulation.
Status | Recruiting |
Enrollment | 1740 |
Est. completion date | December 31, 2025 |
Est. primary completion date | April 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Patients with native duodenal papilla; - Any indication to ERCP +/- biliary sphincterotomy of duodenal major papilla; - Patients able to provide a written informed consent Exclusion Criteria: - ERCP performed for disorders unrelated to biliary tract; - Previous upper gastrointestinal tract surgery; - Presence of a duodenal stricture (either malignant or benign); - Presence of a malignant infiltration of the papilla; - Concomitant anticoagulant and/or P2Y12 inhibitors therapy (clopidogrel, prasugrel, ticagrelor) that precludes the treatment; - INR > 1.5; - Platelets count < 80000/mm3; - Unwillingness to sign written informed consent. |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Roma | |
Italy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome | Roma |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of PEP occurrence | Rate of PEP occurrence distributed between the different native major duodenal papilla types | within 48 hours after the procedure | |
Secondary | Rate of difficult biliary cannulation | Rate of difficult biliary cannulation (> 5 cannulation attempts and/or > 5 minutes attempting to cannulate biliary duct and/or at least one passage in the pancreatic duct) distributed between the different native major duodenal papilla types | during the procedure | |
Secondary | Rate of difficult biliary cannulation | Rate of difficult biliary cannulation distributed between the different types of the intramural papillary segments on fluoroscopic images | during the procedure | |
Secondary | Rate of intraoperative complications | Rate of intraoperative complications distributed between the different native major duodenal papilla types | during the procedure | |
Secondary | Rate of postoperative complications except for PEP | Rate of postoperative complications except for PEP (up to 48 hours after ERCP) distributed between the different native major duodenal papilla types | within 48 hours after the procedure | |
Secondary | Difference in the rate of difficult biliary cannulation | Difference in the rate of difficult biliary cannulation between ERCP experts (>300 performed procedures) and fellows (<300 performed procedures) | during the procedure | |
Secondary | occurrence of intra- and post-procedural complications | To evaluate the occurrence of intra- and post-procedural complications but PEP, fluoroscopic morphology of the papillary segment of distal bile duct, perioperative and intraoperative risk factors | within 48 hours after the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546867 -
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
|
N/A | |
Terminated |
NCT02241512 -
IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis
|
Phase 2 | |
Completed |
NCT00222092 -
Somatostatin, Octreotide, Pentoxyfilline in the Prevention of Post-ERCP Pancreatitis and Molecular Markers
|
Phase 4 | |
Completed |
NCT05310409 -
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
|
||
Not yet recruiting |
NCT06260878 -
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT04770857 -
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
|
||
Completed |
NCT02641561 -
Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
|
Phase 3 | |
Active, not recruiting |
NCT04145336 -
7 cm vs. 5 cm Pancreatic Stents for the Prevention of Post-ERCP Pancreatitis in High-risk Patients
|
N/A | |
Completed |
NCT03629600 -
Trial of Aggressive Hydration Versus Rectal Indomethacin for Prevention of Post-ERCP Pancreatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT03756116 -
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
|
N/A | |
Recruiting |
NCT05664074 -
Rectal Indomethacin vs Intravenous Ketorolac
|
Phase 4 | |
Completed |
NCT02308891 -
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05336630 -
Study of Forceps Cannulation During ERCP
|
N/A | |
Recruiting |
NCT05857514 -
Randomized Controlled Trial of Rectal Indomethacin Versus Combined Pancreatic Stent Placement and Rectal Indomethacin for Preventing Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT05267379 -
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
|
||
Recruiting |
NCT05947461 -
Prevention of Post-ERCP Pancreatitis by Indomethacin vs Diclofenac
|
N/A | |
Completed |
NCT03098082 -
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
|
N/A | |
Recruiting |
NCT02839356 -
Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis
|
Phase 4 | |
Recruiting |
NCT02830984 -
ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP
|
N/A | |
Completed |
NCT01673763 -
Post-ERCP Pancreatitis Prevention by Stent Insertion
|
N/A |